Loading organizations...
Loading organizations...
HYPNO VR is a technology company.
HypnoVR develops certified digital therapies leveraging virtual reality to reduce pain and anxiety. Its core product provides therapeutic multisensory immersion through medical hypnosis delivered via VR. This Class 1 medical device offers a scientifically validated, non-pharmacological approach to patient care, utilizing immersive experiences to manage discomfort across various medical settings.
The company was founded in 2016 by a team combining medical and entrepreneurial expertise: Dr. Denis Graff and Dr. Chloé Chauvin, both anaesthetists and hypnotherapists, alongside entrepreneur Nicolas Schaettel. Their founding insight centered on harnessing modern technology to demystify neuroscience and cognitive science, thereby improving patient experiences by offering effective, accessible digital therapeutic options.
HypnoVR’s solution is adopted by healthcare institutions, finding application in areas such as anaesthesia, critical care, surgery, dental practices, and medical imaging. The company's vision is to empower patients to actively participate in their care, striving to ensure that the largest possible number of individuals benefit from a less painful and stressful course of medical treatment, ultimately freeing the potential of their own brains.
HYPNO VR has raised $5.6M across 2 funding rounds.
HYPNO VR has raised $5.6M in total across 2 funding rounds.
HypnoVR is a French health tech company that develops certified digital therapies combining medical hypnosis with virtual reality (VR) to reduce pain and anxiety in healthcare settings.[1][3][5] Its core product is an ISO13485-certified Class 1 medical device delivering personalized, multisensory immersion via VR headsets, featuring hypnotic sessions, musicotherapy, and high-definition 3D environments, enabling sessions to start in under a minute.[1][2][5] The solution serves healthcare professionals and patients across 30+ medical specialties like anesthesia, surgery, dental care, imaging, and critical care, addressing stress and anxiety that affect 60-80% of hospitalized patients by offering a non-pharmacological alternative that cuts pain by up to 41%, boosts well-being by 69%, and integrates into care pathways to lower medication use and hospital stays.[1][4][5] Adopted by 300+ institutions with 18 published clinical studies, HypnoVR shows strong growth through scientific validation and partnerships.[1][4]
HypnoVR was founded in 2016 in Strasbourg, France, by two anesthesiologists and hypnotherapists, including Dr. Chloé Chauvin, who now serves as Scientific Director.[1][3][4][7] The idea emerged from their daily medical routines, aiming to create a medically aligned VR solution for hypnosis to manage pain and anxiety effectively and accessibly.[1][4][7] Early development focused on designing turnkey software validated by clinical studies, earning CE marking as a Class 1 medical device in September 2018.[2] Pivotal moments include building an ecosystem of scientific partners for R&D, publishing 18 studies, and expanding to 300+ healthcare institutions, driven by the founders' expertise in neurology, neurosciences, and cognitive sciences.[1][2][4]
(Note: Results [6] reference a distinct U.S.-based "Hypnos Virtual" focused on bio-identical virtual nature, unrelated to HypnoVR's medical hypnosis.[6])
HypnoVR rides the wave of digital therapeutics and VR in healthcare, targeting non-pharmacological pain/anxiety management amid rising opioid concerns and demand for patient-centered care.[1][3][5] Timing aligns with VR headset accessibility and post-2018 regulatory approvals, enabling rapid scaling to 300+ institutions.[1][2] Favorable market forces include evidence-based validation (18 studies) differentiating it from competitors like PsyTech VR (CBT/EMDR focus), AppliedVR, Neurovirt (rehab), and Neuro Rehab VR (neuro PT), positioning HypnoVR as a pioneer in hypnosedation.[3][4] It influences the ecosystem by demystifying neurosciences, fostering clinician adoption, reducing medication reliance, and inspiring R&D in immersive therapies.[1][2][4][5]
HypnoVR is poised for expansion into chronic pain, sleep disorders, and workplace wellness, leveraging its R&D ecosystem for new physiological/interactive features and global partnerships.[1][4] Trends like AI-enhanced personalization, broader VR adoption in hospitals, and regulatory support for digital meds will propel growth, potentially amplifying its 300+ institution footprint. Its influence may evolve from niche hypnosedation tool to mainstream care standard, empowering patients as active participants while equipping clinicians with proven, easy alternatives to drugs—reinforcing its mission to make treatments less painful and stressful for the greatest number.[1][5]
HYPNO VR has raised $5.6M in total across 2 funding rounds.
HYPNO VR's investors include Akiles, Banque des Territoires, Capital Grand Est, Alexandre Jouve, Guillaume Richard, Bpifrance, Daniel Caille, La Javaness, Guy Paillaud, Jeremy Dillard CPA, CGMA, Maurice Berenger.
HYPNO VR has raised $5.6M across 2 funding rounds. Most recently, it raised $5.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $5.0M Series A | Akiles, Banque des Territoires, Capital Grand Est, Alexandre Jouve | Guillaume Richard, Bpifrance |
| Jun 1, 2018 | $590K Seed | Daniel Caille, Guillaume Richard, La Javaness | Guy Paillaud, Jeremy Dillard CPA, CGMA, Maurice Berenger, Bpifrance |